The shortcomings in the 340(b) program have been studied for years. One reason for the lack of action is that the implications of these shortcomings have not been presented in a manner that demonstrates they affect the consumer. In essence it appears that certain commercial sectors, pharmacies and hospitals, are benefiting at the cost of the pharmaceutical industry.
One purpose of this Interactive Public Docket(IPD) is to subject this public policy issue to an informed analysis with an interactive capability for all interested stakeholders to express their views and submit relevant data. To this end CRE controls all original posts on this page, the home page, but interested stakeholders may post directly on the two forums to the right of this page. Our readers can, however, post comments on CRE articles on the home page but they cannot post a new article.